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Highlights 
> We examined activity profiles of double-point modified analogues of vitamin D2. 
> The analogues were less toxic in vivo than 1,25D. 
> Pro-differentiating activities of analogues were stronger than that of 1,25D. 
> The analogues upregulated expression of CYP24A1 and CD14 stronger than 1,25D. 
> Neither calcemic, nor pro-differentiation effects were correlated to VDR binding. 
 
Abstract 
1,25-dihydroxyvitamin D3 (1,25D), a steroid hormone which regulates calcium/phosphate 
homeostasis, has a broad spectrum of anti-cancer activities, including differentiation of acute 
myeloid leukemia (AML) cells. In order to avoid undesirable side effects such as 
hypercalcemia, low-calcemic analogues should be produced for therapeutic purposes. In this 
paper, we describe biological activities of double-point modified analogues of vitamin D2 and 
we compare them to 1,25D and to paricalcitol, the drug used to treat secondary 
hyperparathyroidism. In vivo, our new analogues have lower calcemic effects, and lower 
toxicity in comparison to 1,25D. They have enhanced pro-differentiating and transcription-
inducing activities in AML cells. Interestingly, differentiation effects do not correlate with the 
affinities of the analogues to the vitamin D receptor (VDR). 
Keywords: vitamin D analogues; vitamin D receptor; leukemia; differentiation; calcemic 
effects; keratinocytes. 
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1. Introduction 
1,25-dihydroxyvitamin D3 (1,25D), a well known anti-rachitic agent [1], also has antitumor 
and pro-differentiating activities towards cancer cells [2, 3]. This is why many 1,25D 
analogues with improved anti-proliferative and pro-differentiating activities, as well as lower 
calcemic effects have been designed [4, 5]. Mechanistic studies of 1,25D analogues provide 
important information that allow us to determine which structural modifications of the 1,25D 
molecule are responsible for their changed biological properties. 1,25D exerts most of its 
biological functions via the vitamin D receptor (VDR) [6]. Many of VDR target genes are 
connected with the calcium/phosphate homeostasis, but also with anti-proliferative and pro-
differentiating actions of 1,25D in non-calcemic tissues. CYP24A1, the gene most strongly 
regulated by VDR, encodes an enzyme responsible for degradation of 1,25D [7]. Another 
primary VDR-target gene is CD14, a monocytic cell differentiation marker, and a co-receptor 
for bacterial lipopolysaccharide, characteristic for monocytes and macrophages [8, 9]. 
It has been long believed in the field that only subtle changes to the structure of vitamin D 
might result in beneficial changes in the activity profile. Therefore, all the vitamin D drug 
substances were modified in a single point of the molecule. This is why in our search for 
vitamin D analogues of selective activity profile we modified up to now the molecule 
exclusively in the aliphatic side-chain.  The most active analogues we obtained contained one-
carbon unit extended (24a-homo) and rigidified (conjugated diene) side-chain (PRI-1906), 
additionally homologated at both terminal carbons (PRI-1907).  
In our attempt to lower the toxicity of our PRI-1907 and to increase its biological activity we 
have now synthesised new generation of analogues of 1,25-dihydroxyvitamin D2 modified in 
two distinct parts of molecule. In these structures we have combined our optimised side-chain 
of PRI-1906 and PRI-1907 [10-12] with the known 19-nor modification. This modification 
was previously introduced in the structure of a drug substance (paricalcitol, PRI-5100) and its 
24-epi analogue (PRI-5101) [13], and we use them as a reference in our experiments. In this 
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paper we present our in vivo and in vitro evaluation of the resulting analogues PRI-5201 and 
PRI-5202 compared to the previously obtained ones and to 1,25D. The structures of the 
analogues are presented in Fig. 1. 
2. Materials and Methods 
2.1. Chemicals and antibodies: 
1,25D and analogues were synthesised at the Pharmaceutical Research Institute (Warsaw, 
Poland). Antibodies for flow cytometry were from ImmunoTools (Friesoythe, 
Germany). Antibodies for western blots and chemiluminescence blotting substrate were from 
Santa Cruz (Santa Cruz, CA). 
 
2.2. Cell lines, flow cytometry and western blots: 
HL60 cells (Institute of Immunology and Experimental Therapy in Wroclaw, Poland) and 
HaCat cells (Dr. Miguel Quintanilla, Instituto de Investigaciones Biomedicas Alberto Sols, 
Madrid, Spain) were cultured using standard conditions. HL60 cells were incubated, labeled 
and analysed by flow cytometry as we have described before [10]. Western blotting was 
performed using nuclear fractions from cells as previously described [10]. 
2.3. cDNA synthesis and Real time PCR: 
Total RNA was isolated and transcribed into cDNA. Then Real time PCR reaction was 
performed as previously described [10]. 
 
2.4. Human VDR binding assay: 
Binding affinity to VDR was evaluated using a PolarScreen™ Vitamin D Receptor 
Competitor Assay Kit under manufacturer conditions (Life Technologies). The polarised 
fluorescence was measured using Envision (Perkin-Elmer). All compounds were evaluated 
within the range 10-11 to 10-5 M, IC50 values were calculated using the average of  values 
obtained. 
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2.5. Calcemic activity in vivo: 
All animals studies were approved by the University of Santiago de Compostela Ethics 
Committee for Animal Experiments. Male CD-1 mice (age matched, between 6 and 8 weeks) 
were obtained from Charles River Laboratories (L’Arbresle, France). The compounds were 
resuspended  in sesame oil and administered intraperitoneally (0.3µg/kg) every other day for 
21 days. Ethanol resuspended in sesame oil was used as the control for this experiment. 
Serum calcium levels were measured a day after the last dose using the QuantiChom Calcium 
Assay Kit (BioAssay Systems, Hayward, CA, USA) following manufacturer’s guidelines. The 
weight of mice was measured every week. 
 
2.6. Statistical analysis: 
All experiments were repeated at least three times. Values are expressed as means ± SD. Dose 
response curves for cell differentiation and competitive VDR binding, calculation of EC50 and 
IC50 values, as well as analysis of statistical significance (ANOVA followed by t-tests) were 
performed using GraphPad Prism 6 software (San Diego, CA, USA). 
 
3. Results 
3.1. Calcemic activities in vivo: 
First, we tested calcemic activities of our compounds in mice. The calcium serum levels 
induced by 1,25D and by all analogues, compared to the vehicle (ethanol) treated mice, are 
presented in Fig. 2A. Since toxic effects are not always directly connected to calcemia 
induced by 1,25D or by the analogues, we also examined the extent to which administration 
of the compounds affected the body weight of mice. The changes in body weight are related 
to overall toxicity (Fig. 2B). The results show that all of the tested analogues are less calcemic 
than 1,25D. The analogues PRI-1907, and to lower extent PRI-5202, exerted some general 
toxicity, similarly to 1,25D, as they affected weight gain of the mice. It is noteworthy, that 
mice receiving analogue PRI-5201, showed no significant change in body weight when 
compared to vehicle-treated mice. 
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3.2. Binding of analogues to VDR: 
Since VDR is the primary target for 1,25D and analogues in cells, it is important to study the 
affinities of given analogues to this protein [14]. The experiments were performed using a 
fluorescence polarisation (FP)-based competition assay. The binding of analogues to VDR 
was tested over a wide range of concentrations and was compared to binding of 1,25D to the 
receptor. Dose-response curves were plotted (data not shown), and  IC50 values were 
calculated from these dose-response curves (Table 1). 
 
3.3. Differentiation of HL60 cells: 
HL60 cells were used to determine how the subtle changes introduced to the structure of 
analogues influenced their pro-differentiating activities [15, 16]. The cells were exposed to 
compounds at a wide concentration range for 96 h and then the expression of 
monocyte/macrophage differentiation markers CD11b and CD14 was studied using flow 
cytometry. Since treated cells expressed CD14 a greater extent than CD11b, we therefore 
present the data obtained for this differentiation marker. Dose-response curves allowed us to 
calculate EC50 value for each analogue (Table 1). This data confirmed our earlier findings that 
analogue PRI-1907 is about one order of magnitude more active than 1,25D [10, 12], and it 
also shows that the new analogues, PRI-5201 and PRI-5202 are even more active in inducing 
AML cell differentiation than PRI-1907. 
3.4. Transcription-inducing activities of 1,25D and analogues: 
1,25D and its analogues are ligands of VDR, a receptor which is a ligand-activated 
transcription factor. The  activity of analogues can be measured by the levels of transcription 
which they induce. In order to compare the transcriptional activities of the analogues we 
tested the expression of CYP24A1 and CD14 genes in HL60 cells exposed for 48 h (CD14) 
and 96 h (CYP24A1) to the analogues at 1 nM and 10 nM (not shown) concentrations. The 
results of CYP24A1 expression are presented in Fig. 3A, and CD14 expression in Fig. 3B. 
Again, the analogues PRI-1907, PRI-5201 and PRI-5202 are more active than 1,25D, 
especially at 1 nM concentrations.  
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3.5. Nuclear translocation and accumulation of VDR in response to analogues: 
The ligand-induced translocation of VDR into the nucleus is a critical step required for 
transcriptional activity of VDR [17]. Given that VDR nuclear accumulation and pro-
differentiating activity were correlated for previously tested analogues, we therefore studied 
how new analogues influence the levels of VDR protein in HL60 cells. We analysed VDR 
levels in nuclear fractions of cells exposed for different times to analogues at 1 nM 
concentration. Actin was used as a control, as it is a protein that does not change during HL60 
cell differentiation. A significant increase in the level of VDR in the nucleus was seen as early 
as 3 h after exposing the cells to analogues, but at this time-point the VDR level does not 
correlate with differentiation-inducing activity of the given analogue. At later time-points, 
from 24 h (not shown) to 72 h post treatment, the amount of VDR in the nucleus correlates 
with the differentiation effect (Fig.4).  
 
3.6. Activation of C/EBPβ by 1,25D and analogues: 
In addition, we have examined the ability of tested analogues to increase expression of 
C/EBPβ protein. Our previous studies provided strong experimental evidence that 1,25D up-
regulates expression of this protein in HL60 cells [18] and, it has been  shown that down-
regulation of C/EBPβ  protein levels, using antisense technology, attenuates 1,25D-induced 
differentiation in this cell line [19, 20]. C/EBPβ expression in response to 1,25D treatment is 
undetectable at 24 h but it rises gradually to reach maximal levels at 3-4 days of treatment 
[18]. Therefore, we determined C/EBPβ protein levels in nuclear fractions of HL60 cells 
treated for 72 h with 1 nM  1,25D and analogues. The results are presented as western blots in 
Fig.5 which show that increased nuclear expression of C/EBPβ2 and C/EBPβ3  correlates 
well with the final cell differentiation effect. 
 
3.7. Pro-differentiating activity of analogues towards human keratinocytes: 
In order to determine whether the increased potency of analogues was limited to AML cells, 
we tested the differentiation effects of analogues towards human keratinocyte cell line HaCat 
[21]. After exposure to 1,25D and to other VDR ligands these cells change their growth 
properties and phenotype. This experiment showed in a qualitative manner the ability of 
analogues to induce differentiation of keratinocytes. The results presented in Figure 6 show 
that all the analogues induced phenotype changes to the HaCat cells which are characteristic 
for differentiated cells. 
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4. Discussion 
1,25D is a very active compound with many biological activities, including induction of cell 
differentiation, immunomodulation and inhibition of cell proliferation [2, 3, 22]. 1,25D is also 
a potent regulator of calcium/phosphate metabolism, so when used at pharmacological 
concentrations, it can induce hypercalcemia [1]. To utilise the therapeutic properties of 1,25D, 
it is necessary to obtain analogues that would have increased benefits to risk ratio, as 
compared to 1,25D [5]. The analogues should be selective and should  have increased pro-
differentiating and anti-proliferative, and lowered calcemic activities. Regulation of the 
effective concentration and biological activity of 1,25D is maintained at multiple levels 
including transport of the analogue to the cell, intracellular localisation of the receptor, 
effective activation of transcription and degradation of 1,25D to inactive metabolites [23]. 
Therefore, it is necessary to complete a wide range of experiments to fully characterise new 
vitamin D analogues. 
Our experiments revealed that the new, double-point modified analogues do not increase 
serum calcium levels as much as 1,25D. Their toxic effects, displayed as their ability to 
influence mice body weight, are lower than that of 1,25D, and also lower than toxicity 
induced by PRI-1907, the most active compound out of the single-point modified vitamin D2 
analogues. The pro-differentiating activities of PRI-5201 and PRI-5202 are more than an 
order of magnitude higher than that of 1,25D which suggests that they can be applied at lower 
concentrations to obtain anti-cancer or immunomodulatory effects. New, toxicological 
screening of these analogues, in a broader range of concentrations should reveal whether they 
are suitable for long-term therapy.  
In our previous experiments, we have shown that the high differentiation-inducing potential of 
PRI-1907 correlated with its ability to increase the expression of the master regulator of 
monocyte differentiation, namely the C/EBPβ transcription factor and with upregulation of 
VDR target CD14 gene. The same correlation was observed for double-point modified 
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analogues (PRI-5201 and PRI-5202). The high pro-differentiating activities of PRI-5201 and 
PRI-5202, as compared to PRI-5100 and PRI-5101, cannot be explained by the binding 
affinities of these analogues for VDR. The affinity of PRI-5100 and PRI-5101 is more than 
four times higher than that of 1,25D. Interestingly, the affinity of PRI-5101, with the 
unnatural configuration at C-24 in the side-chain, is higher than that of PRI-5100 with the 
natural side-chain of 1,25-dihydroxyvitamin D2. The affinity of the new analogue PRI-5201 is 
two times lower than that of PRI-5100 and the affinity of PRI-5202 is about seven times 
lower than that of PRI-5100 and PRI-5101. Therefore, we suggest that an interplay of 
different signal transduction pathways, genomic and non-genomic events, and the ability of 
given analogue to stabilise VDR in the cell nucleus of target cells (see Fig.4) are all  
important to eventual biological activity. The combination of selected structural fragments 
(side-chain of analogue PRI-1907 and 19-nor modification) has been shown to be very 
beneficial to the activity profile of vitamin D analogues. Until now analogues PRI-5201 and 
PRI-5202 represent the most active vitamin D compounds we designed, synthesised and 
biologically evaluated. Further modifications of the vitamin D structure leading to the same 
direction as to biological activity are under way in our laboratories. 
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Fig. 1. Structures of 1,25D, PRI-1907, PRI-5100, PRI-5101, PRI-5201, PRI-5202. 
 
 
 
Fig. 2. In vivo effects of 1,25D and analogues.  
A. Calcium levels in mice treated with the natural hormone 1,25D and compounds. Five mice per 
group were treated with 0.3 µg/kg of analogues, 1,25D or control every other day during 3 weeks, and 
calcium levels were measured on day 21.  Error bars represent the standard deviation (SD). Analogues 
were compared to 1,25D,  ****P ≤ 0.0001. B. Effect of analogues on body weight of mice. Mice were 
weighed every other day for 3 weeks. Analogues were compared to either the control (#) or to 1,25D 
(*) * P ≤0.05, **P ≤0.01, ### P ≤ 0.001, #### P≤0.0001,  ns P > 0.05. 
 
A B 
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Fig. 3. Impact of 1,25D and analogues on mRNA  levels. 
A. HL60 cells were exposed to 1 nM 1,25D and analogues for 96 h and then the expression of 
CYP24A1 mRNA was tested in Real Time PCR. The  graph shows mean values (±SEM) of fold 
changes in CYP24A1 mRNA levels relative to GAPDH. B. HL60 cells were exposed to 1 nM 1,25D 
and analogues for 48 h and then the expression of CD14 mRNA was tested in Real Time PCR. The  
graph shows mean values (±SEM) of fold changes in CD14 mRNA levels relative to GAPDH. 
 
 
 
 
 
Fig. 4. Nuclear localisation of VDR protein in HL60 exposed to 1,25D or analogues. 
HL60 cells were exposed to 1,25D or analogues at 1 nM concentration for 3 h and 72 h and 
then expression of VDR was determined in the nuclear fractions. 
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Fig. 5. C/EBPβ isoforms in HL60 cells treated with 1nM 1,25D and analogues.  
HL60 cells were treated for 72 h with 1 nM 1,25D and analogues. The nuclear fraction was 
separated by electrophoresis and transferred onto PVDF membrane, and probed with 
antibodies against C/EBPβ, and β-actin as fractionation/loading controls. In addition to the 
three C/EBPβ isoforms, unidentified bands, possibly cleavage products of C/EBPβ, are 
present. 
 
 
 
 
 
 
Fig. 6. Differentiation of HaCat cells in response to 1,25D or analogues.    
Phase-contrast micrographs showing the induction by analogues of a differentiated adhesive 
epithelial phenotype in human HaCat cells. The cells were treated with analogues at 100 nM 
for 48 h. 
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Table. 1. VDR binding and differentiation-inducing activities of 1,25D and analogues PRI-
1907, PRI-5100, PRI-5101, PRI-5201 and PRI-5202. 
 VDR Binding Differentiation 
 IC50 (M) RBAa EC50 (M) EMR 
1,25D 2.320 e-009 100 5.347 e-010 1 
PRI-1907 6.172 e-009 37 5.952 e-011 0.11 
PRI-5100 5.599 e-010 414 1.128 e-009 2.12 
PRI-5101 4.921 e-010 471 1.179e-009 2.22 
PRI-5201 1.193 e-009 194 3.397 e-011 0.063 
PRI-5202 3.598 e-009 64 1.788e-011 0.033 
The VDR binding affinity is expressed as IC50 and percentage activity. aThe potency of 1,25D 
is normalised to 100. RBA: relative binding affinity. Cell differentiation activity is expressed 
as EC50 and EMR: effective molar ratio (EC50 analogue/EC50 1,25D). 
